| answer text |
<p>The Department has been working intensively to address issues with the supply of
some epilepsy medications, and as a result we have helped to resolve issues with Tegretol
200 milligram and 400 milligram prolonged release tablets, and Tegretol 100 milligram
immediate release tablets. We are aware of a shortage of Tegretol 100 milligram/5
millilitre liquid, but have been advised that resupplies are expected this month.
We are continuing to work closely with manufacturers, including Novartis, to help
ensure the continued supply of these medicines for patients in the United Kingdom,
for example by asking suppliers to expedite deliveries.</p><p>Whilst we can’t always
prevent supply issues, we have a range of well-established tools and processes to
mitigate risks to patients. These include close and regular engagement with suppliers,
use of alternative strengths or forms of a medicine to allow patients to remain on
the same product, expediting regulatory procedures, sourcing unlicensed imports from
abroad, adding products to the restricted exports and hoarding list, use of Serious
Shortage Protocols, and issuing National Health Service communications to provide
management advice and information on the issue to healthcare professionals, so they
can advise and support their patients.</p>
|
|
